(PPH) Pharmaceutical - NASDAQ
ETF Category: Health | Exchange: NASDAQ (USA) | Market Cap: 892m USD | Total Return: 19.9% in 12m
Avg Turnover: 14.9M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The VanEck Pharmaceutical ETF (PPH) tracks a benchmark index comprised of U.S.-listed pharmaceutical companies, including domestic firms, foreign entities, and medium-capitalization stocks. The fund maintains a concentrated, non-diversified portfolio, allocating at least 80% of its assets to the underlying index components to provide exposure to the global drug manufacturing sector.
The pharmaceutical business model relies heavily on high research and development (R&D) expenditures and the protection of intellectual property through long-term patents. This sector is characterized by rigorous regulatory approval processes and a reliance on blockbuster drugs to offset the costs of failed clinical trials.
Investors looking for deeper fundamental insights may find it useful to evaluate these holdings on ValueRay.
- Medicare price negotiations impact revenue margins for top pharmaceutical holdings
- Blockbuster drug patent expirations trigger revenue losses to generic competitors
- FDA approval cycles for late-stage pipelines dictate long-term valuation growth
- Global healthcare spending levels influence demand for branded chronic medication
- Strategic mergers and acquisitions activity drives premium valuations within the fund
As of June 14, 2026, the stock is trading at USD 106.47 with a total of 68,877 shares traded.
Over the past week, the price has changed by +0.68%,
over one month by +4.26%,
over three months by +2.85% and
over the past year by +19.94%.
Pharmaceutical has no consensus analysts rating.